PANCREATIC CANCER RESECTABLE
Clinical trials for PANCREATIC CANCER RESECTABLE explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC CANCER RESECTABLE trials appear
Sign up with your email to follow new studies for PANCREATIC CANCER RESECTABLE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail of drugs takes on tough pancreatic cancer
Disease control Not yet recruitingThis early-stage trial tests whether adding three new drugs (nogapendekin alfa inbakicept, sotevtamab, and zabadinostat) to standard chemotherapy can safely shrink pancreatic tumors that are hard to remove. About 30 adults with borderline resectable or locally advanced pancreatic…
Matched conditions: PANCREATIC CANCER RESECTABLE
Phase: PHASE1 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New triple therapy aims to shrink pancreatic tumors before surgery
Disease control Not yet recruitingThis phase 2 trial tests whether giving a combination of surufatinib (a targeted therapy), toripalimab (an immunotherapy), and chemotherapy before surgery can help people with high-risk or borderline resectable pancreatic cancer. The study will enroll 30 participants and track ho…
Matched conditions: PANCREATIC CANCER RESECTABLE
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New trial aims to improve survival for a tough pancreatic cancer
Disease control Not yet recruitingThis phase 3 trial will test whether giving chemotherapy before surgery helps people with resectable left-sided pancreatic cancer live longer compared to surgery alone. About 381 participants will be randomly assigned to either neoadjuvant chemotherapy (FOLFIRINOX or gemcitabine/…
Matched conditions: PANCREATIC CANCER RESECTABLE
Phase: PHASE3 • Sponsor: Helsinki University Central Hospital • Aim: Disease control
Last updated Jun 26, 2026 13:50 UTC
-
Gene test could tailor chemo for tough pancreatic cancers
Knowledge-focused Not yet recruitingThis study aims to see if using a patient's genetic signature to choose chemotherapy can improve outcomes for people with borderline resectable pancreatic cancer. About 367 participants will receive standard chemotherapy, and researchers will track how long they live without majo…
Matched conditions: PANCREATIC CANCER RESECTABLE
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC